Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.48 |
| ▸ | CNR1 | P21554 | 10/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591950 | 0.87 | CNR1 (0.45) | CNR2CNR1PTGER1 | |
| SCHEMBL3591440 | 0.84 | CNR1 (0.46) | CNR2CNR1 | |
| SCHEMBL3591947 | 0.84 | CNR1 (0.39) | CNR2CNR1 | |
| SCHEMBL4357106 | 0.80 | CNR1 (0.47) | CNR2CNR1 | |
| SCHEMBL3588519 | 0.80 | CNR1 (0.44) | CNR2CNR1 | |
| SCHEMBL3603195 | 0.78 | CNR2 (0.42) | CNR2CNR1BRD4 | |
| SCHEMBL4357149 | 0.76 | CNR1 (0.47) | CNR2CNR1 | |
| SCHEMBL31368063 | 0.71 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL3587029 | 0.71 | CNR1 (0.40) | CNR2CNR1 | |
| SCHEMBL3594920 | 0.68 | PTGER1 (0.41) | PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004240-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20100004240-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20100004240-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| EP-2041127-A2 | INDOLE COMPOUNDS | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006795-A2 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006795-A2 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004240-A1 | Indole Compounds | IDO1, TPH1, IDO2 | CNR2 62/4885CNR1 43/4885DPP4 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.